Nasal clues could unlock new asthma attack treatment
NCT ID NCT04748055
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This pilot study tracks changes in a specific inflammatory marker (IL-1β) in the nasal passages of adolescents during an asthma attack. Researchers collect nasal fluid samples daily for five days during an attack and compare them to baseline samples taken when the participant is well. The goal is to understand when IL-1β peaks, which could help determine the best time to give a drug called anakinra in future studies. Participants are teens aged 12–21 with persistent asthma who use daily controller medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help design a future trial testing anakinra (a drug that blocks IL-1) to reduce inflammation during asthma attacks.
What could go wrong
This is a small pilot study with only 40 participants, focused on measuring biological changes rather than testing a treatment. Results may not lead to a successful therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27514, United States